Literature DB >> 15886228

Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting.

John G Esposito1, Scott G Thomas, Lori Kingdon, Shereen Ezzat.   

Abstract

Growth hormone (GH) treatment reverses the muscle loss allegedly responsible for diminished aerobic capacity and increased fatigue in patients with HIV-associated wasting. This study examined whether submaximal measures of physical performance can be used as objective measures of the functional impact of GH treatment-induced anabolism. We randomized 27 HIV-positive men [mean (SD) age, 43.9 (7.2) yr; body mass, 71.9 (10.4) kg; BMI, 23.1 (2.8) kg/m2] with unintentional weight loss despite antiretroviral therapy to receive GH (6 mg) or placebo in a double-blinded, placebo-controlled, cross-over trial with a 3-mo washout. Lean body mass (LBM), maximum oxygen uptake (Vo2 peak), ventilatory threshold (VeT), 6-min walk test (6MWT) distance and work, profile of mood states (POMS) fatigue and vigor scores, and Nottingham health profile (NHP) energy and physical mobility scores were measured. LBM significantly increased after 3 mo of GH treatment vs. placebo (means +/- SE, 3.7 +/- 0.6 vs. 0.3 +/- 0.4 kg; P < 0.001). VeT significantly improved (17.6 +/- 3.7 vs. -5.9 +/- 2.5%; P < 0.001), but Vo2 peak did not change significantly. 6MWT distance improved (24.9 +/- 9.7 vs. 19.9 +/- 11.6 m; P > 0.05) and 6MWT work increased significantly more after 3 mo of GH treatment (33.3 +/- 8.8 vs. 16.5 +/- 7.5 kJ; P < 0.05). POMS scores of fatigue and vigor and the NHP score of energy improved, yet the changes were not statistically significant. GH treatment improved VeT linearly to the increase in LBM (r =0.43, P = 0.037) and 6MWT work (r = 0.51, P = 0.008), and the increase in 6MWT work correlated with increase in LBM (r = 0.45, P = 0.024). Improvement in 6MWT work above the median (27.3 kJ) showed a decrease in fatigue (r = -0.62, P = 0.024). We concluded that GH treatment-induced LBM gains in HIV-associated wasting were functionally relevant, as determined by effort-independent submaximal measures of cardiopulmonary exercise testing.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15886228     DOI: 10.1152/ajpendo.00013.2005

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  9 in total

Review 1.  The Safety and Efficacy of Growth Hormone Secretagogues.

Authors:  John T Sigalos; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2017-04-08

2.  Six-minute walk test for persons with mild or moderate disability from multiple sclerosis: performance and explanatory factors.

Authors:  Jane L Wetzel; Donna K Fry; Lucinda A Pfalzer
Journal:  Physiother Can       Date:  2011-04-13       Impact factor: 1.037

3.  The Use of Recombinant Human Growth Hormone to Protect Against Muscle Weakness in Patients Undergoing Anterior Cruciate Ligament Reconstruction: A Pilot, Randomized Placebo-Controlled Trial.

Authors:  Christopher L Mendias; Elizabeth R Sibilsky Enselman; Adam M Olszewski; Jonathan P Gumucio; Daniel L Edon; Maxwell A Konnaris; James E Carpenter; Tariq M Awan; Jon A Jacobson; Joel J Gagnier; Ariel L Barkan; Asheesh Bedi
Journal:  Am J Sports Med       Date:  2020-05-26       Impact factor: 6.202

Review 4.  Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting.

Authors:  Norleena P Gullett; Gautam Hebbar; Thomas R Ziegler
Journal:  Am J Clin Nutr       Date:  2010-02-17       Impact factor: 7.045

5.  GH/GHRH axis in HIV lipodystrophy.

Authors:  Takara L Stanley; Steven K Grinspoon
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

6.  Prediction of cardiorespiratory fitness in older men infected with the human immunodeficiency virus: clinical factors and value of the six-minute walk distance.

Authors:  Krisann K Oursler; Leslie I Katzel; Barbara A Smith; Wayne B Scott; David W Russ; John D Sorkin
Journal:  J Am Geriatr Soc       Date:  2009-09-28       Impact factor: 5.562

7.  Health-related quality of life and physical functioning in people living with HIV/AIDS: a case-control design.

Authors:  Chidozie Emmanuel Mbada; Olaniyi Onayemi; Yewande Ogunmoyole; Olubusola Esther Johnson; Christopher O Akosile
Journal:  Health Qual Life Outcomes       Date:  2013-06-26       Impact factor: 3.186

8.  Boosting The Late Blooming Male: Use of growth promoting agents in the athlete with constitutional delay of growth and puberty.

Authors:  Vanessa A Curtis; David B Allen
Journal:  Sports Health       Date:  2011-01       Impact factor: 3.843

9.  Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.

Authors:  David R Clemmons; Sam Miller; Jean-Claude Mamputu
Journal:  PLoS One       Date:  2017-06-15       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.